Latera RCT - Latera vs. Sham Control for Lateral Nasal Valve Collapse

Latera Randomized Controlled Trial (RCT) - Latera® Absorbable Nasal Implant vs. Sham Control for Lateral Nasal Valve Collapse

The primary objective of the LATERA RCT is to demonstrate the superiority of the Latera Implant to improve nasal breathing, compared with a Sham Control procedure.

To evaluate the Latera Absorbable Nasal Implant (Latera Implant) Implant versus Sham Control in subjects with nasal valve collapse due to or primarily due to insufficient cartilaginous support of the lateral nasal wall.

Subjects must meet the following criteria to be included in the study:

1. Adults aged 18 and above;
2. Understands and provides written informed consent;
3. Stated willingness to comply with all study procedures, post-treatment care and availability for the duration of the study follow up of 2 years;
4. In good general health as evidenced by medical history;
5. NOSE score ≥55;
6. Dynamic bi-lateral nasal wall insufficiency as confirmed by Positive Modified Cottle Maneuver;
7. Nasal and facial anatomy appropriate to receive the Latera Implant;
8. Documented failure of benefit after at least 4 weeks of conservative medical management, including, for example, antihistamines or nasal steroids, evidenced by lack of efficacy or tolerability.

Subjects meeting any one of the following criteria will be excluded for the study:

1. Unable to tolerate or not a candidate for procedures performed under local anesthesia;
2. Pathology other than lateral wall insufficiency (e.g. septal deviation, turbinate or adenoid hypertrophy, polyps, sinusitis, rhinitis) is the primary contributor to airway obstruction;
3. Requires or is anticipated to require any other concurrent nasal procedures (e.g. Functional Endoscopic Sinus Surgery (FESS), rhinoplasty, sinuplasty, septoplasty, or turbinate reduction) outside of the index procedure within 12 months after the index procedure;
4. FESS, sinuplasty, septoplasty, inferior turbinate reduction, or rhinoplasty within the past 6 months;
5. Any other rhinoplasty procedures are planned or planned usage of external dilators within 24 months after the index procedure;
6. Permanent nasal implant of any type (e.g. autologous, homologous, or synthetic graft) or dilator;
7. Presence of concomitant inflammatory or infectious conditions or unhealed wounds in the treatment area (e.g., vestibulitis, vasculitis, active acne),
8. Currently using chronic systemic steroids or recreational intra-nasal drugs;
9. Currently has cancerous or pre-cancerous nasal lesions, has had radiation in the treatment area, or is currently receiving chemotherapy;
10. History of a significant healing disorders including hypertrophic scarring, or keloid formation;
11. Poorly controlled diabetes mellitus;
12. Known or suspected allergy to PLA or other absorbable implant materials in the Latera Implant;
13. Severe obstructive sleep apnea (OSA) and cannot or is unwilling to refrain from continuous positive airway pressure (CPAP) for up to 2 weeks post-procedure based on expected healing needs and mask types, in agreement with the treating physician;
14. Female subjects, of child bearing potential, known or suspected to be pregnant or are lactating;
15. Any other presenting condition that, in the medical opinion of the investigator, would disqualify the subject from the study.